Amesite Inc. stock surges despite market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Should l Buy AMST?
Source: Barron's
Amesite Inc. shares rose by 27.78% as it crossed above its 5-day SMA, indicating strong buying interest.
The significant price increase comes amid no specific news regarding the company, suggesting a sector rotation as investors shift focus to stocks like Amesite that may offer growth potential despite broader market weakness. The Nasdaq-100 and S&P 500 are both down, highlighting the contrasting performance of Amesite.
This movement could indicate a growing confidence in Amesite's business model or upcoming developments that have not yet been publicly disclosed, positioning the company favorably in a challenging market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMST
About AMST
Amesite Inc. is a technology company. The Company focused on building and commercializing AI-powered solutions for the healthcare sector. The Company specializes in the development and marketing of business-to-consumer (B2C) and business-to-business (B2B) artificial intelligence (AI)-driven solutions, including its higher ed platform that offers professional learning. The Company's platform utilizes infrastructure to deliver both Amesite Engage for higher education and NurseMagic for healthcare. NurseMagic is a mobile app for healthcare professionals, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations. NurseMagic is designed for use across various healthcare modalities, such as skilled nursing, assisted living, memory care, home health, and rehabilitation centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amesite Closes Private Placement of 696,866 Shares
- Private Placement Completed: Amesite Inc. successfully closed a private placement of 696,866 shares of common stock at a price of $1.435 per share, expected to generate approximately $2.6 million in gross proceeds, thereby strengthening its capital base for future growth.
- Warrants Issued: The placement included unregistered Series A-1 and A-2 warrants, each allowing the purchase of 696,866 shares at an exercise price of $1.435 per share, with potential additional gross proceeds of approximately $5.2 million if fully exercised.
- Insider Participation: Company executives and board members participated in an insider-led private placement at a premium to market, involving 418,118 shares and corresponding warrants, reflecting management's confidence in the company's future prospects.
- Compliance and Registration: The placement was conducted in accordance with Nasdaq rules and under a registered S-3 filing with the SEC, ensuring compliance and laying the groundwork for future capital operations.
See More
Amesite Inc. Completes Sale of 696,866 Shares in Direct Offering
- Stock Offering Details: Amesite Inc. announced the issuance of 696,866 shares of common stock at a price of $1.435 per share, with expected gross proceeds of approximately $2 million, reflecting the company's active engagement in capital markets and financing capabilities.
- Warrant Issuance: The company will also issue unregistered Series A-1 and A-2 warrants to investors, each allowing the purchase of 696,866 shares at the same exercise price of $1.435, enhancing future financing flexibility.
- Use of Proceeds: The net proceeds from this offering will be allocated for general corporate purposes, including working capital, indicating the company's strategic intent to expand operations and improve efficiency.
- Market Reaction Expectations: Although there is uncertainty regarding the exercise of the warrants, if fully exercised, they could generate an additional approximately $4 million for the company, further supporting its innovative developments in the healthcare sector.
See More
Amesite Withdraws Public Offering Registration Statement
- Withdrawal of Registration Statement: On April 27, 2026, Amesite Inc. filed a request with the SEC to withdraw its S-1 registration statement originally submitted on April 20, 2026, indicating a significant strategic shift as the company no longer intends to pursue a public offering.
- No Securities Sold: The registration statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering, highlighting potential challenges in the company's financing strategy that may impact future capital operations.
- Core Product Advantage: Amesite's flagship product, NurseMagic™, reduces documentation time for nurses and caregivers from 20 minutes to just 20 seconds, enhancing operational efficiency and is utilized by over 100 professions across 50 states and 21 countries, showcasing its market potential.
- Market Positioning and Compliance: Built on proprietary AI trained on industry-specific data, NurseMagic™ meets HIPAA regulations while improving accuracy and efficiency, indicating the company's strong competitive edge and compliance capabilities in the healthcare sector.
See More
Amesite Partners with Homecare Tech Platform for NurseMagic Integration
- Strategic Partnership Agreement: Amesite Inc. has signed an Electronic Transactions Trading Partner Agreement with a leading homecare technology platform, establishing itself as a compliant trading partner, which is expected to enhance the application of its AI platform NurseMagic™ in the non-acute care market, valued at approximately $1.55 trillion.
- Integration Advantages: By connecting with this platform, NurseMagic™ can streamline electronic visit verification (EVV) processes using standardized formats mandated by CMS and the 21st Century Cures Act, thereby improving compliance efficiency and operational convenience for clients.
- Revenue Growth Momentum: Amesite achieved a 69% quarter-over-quarter revenue increase in Q2 2026, with a 63% revenue growth following the launch of its census-based enterprise subscription model, indicating strong growth potential in the non-acute care market.
- Industry Recognition: NurseMagic™ was named a finalist for Nurse.org's
See More
Amesite's NurseMagic™ Nominated for Best AI Nursing Tool
- Industry Recognition: Amesite's AI healthcare platform, NurseMagic™, has been nominated as a finalist in the AI Nursing Tool category of Nurse.org's 'Best of Nursing Awards', highlighting its impact and credibility in the healthcare sector, thereby enhancing the company's competitive position in the estimated $460–510 billion U.S. post-acute care market.
- Significant Revenue Growth: Following the launch of NurseMagic™ Teams+ in May 2025, the company reported a 2.4x quarter-over-quarter revenue increase, with an 82% revenue growth in the subsequent quarter after launching the enterprise tier, and a further 69% increase in the following period, indicating strong market demand and profitability.
- User-Driven Expansion: By prioritizing service to nurses and caregivers, NurseMagic™ rapidly scaled across all 50 states and over 20 countries, establishing an engaged user community that not only validated the product's effectiveness in clinical workflows but also laid the groundwork for enterprise sales.
- Technological Innovation and Market Potential: The AI-native EMR system of NurseMagic™ is designed to coexist with or replace legacy systems, expected to drive double-digit annual growth in the long-term care and post-acute software market, further solidifying Amesite's market share in this rapidly growing sector.
See More
Clearwater Analytics (CWAN) Acquired by Private Equity Consortium for $8.4 Billion
- Acquisition Announcement: A consortium of private equity firms led by Permira and Warburg Pincus has announced a deal to acquire Clearwater Analytics for approximately $8.4 billion, including debt, indicating strong market interest in investment and accounting software companies.
- Stock Price Reaction: Clearwater Analytics shares surged 7.6% to $23.93 in pre-market trading, reflecting positive investor sentiment regarding the acquisition news, which may enhance the company's future market performance.
- Market Impact: This acquisition not only provides Clearwater Analytics with financial backing but also has the potential to accelerate its technological innovation and market expansion, strengthening its position in the highly competitive software industry.
- Industry Trend: With private equity firms continuing to invest in the software sector, more similar transactions are expected, further consolidating market resources and enhancing industry competitiveness.
See More
Amesite Closes Private Placement of 696,866 Shares
- Private Placement Completed: Amesite Inc. successfully closed a private placement of 696,866 shares of common stock at a price of $1.435 per share, expected to generate approximately $2.6 million in gross proceeds, thereby strengthening its capital base for future growth.
- Warrants Issued: The placement included unregistered Series A-1 and A-2 warrants, each allowing the purchase of 696,866 shares at an exercise price of $1.435 per share, with potential additional gross proceeds of approximately $5.2 million if fully exercised.
- Insider Participation: Company executives and board members participated in an insider-led private placement at a premium to market, involving 418,118 shares and corresponding warrants, reflecting management's confidence in the company's future prospects.
- Compliance and Registration: The placement was conducted in accordance with Nasdaq rules and under a registered S-3 filing with the SEC, ensuring compliance and laying the groundwork for future capital operations.
See More
Amesite Inc. Completes Sale of 696,866 Shares in Direct Offering
- Stock Offering Details: Amesite Inc. announced the issuance of 696,866 shares of common stock at a price of $1.435 per share, with expected gross proceeds of approximately $2 million, reflecting the company's active engagement in capital markets and financing capabilities.
- Warrant Issuance: The company will also issue unregistered Series A-1 and A-2 warrants to investors, each allowing the purchase of 696,866 shares at the same exercise price of $1.435, enhancing future financing flexibility.
- Use of Proceeds: The net proceeds from this offering will be allocated for general corporate purposes, including working capital, indicating the company's strategic intent to expand operations and improve efficiency.
- Market Reaction Expectations: Although there is uncertainty regarding the exercise of the warrants, if fully exercised, they could generate an additional approximately $4 million for the company, further supporting its innovative developments in the healthcare sector.
See More
Amesite Withdraws Public Offering Registration Statement
- Withdrawal of Registration Statement: On April 27, 2026, Amesite Inc. filed a request with the SEC to withdraw its S-1 registration statement originally submitted on April 20, 2026, indicating a significant strategic shift as the company no longer intends to pursue a public offering.
- No Securities Sold: The registration statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering, highlighting potential challenges in the company's financing strategy that may impact future capital operations.
- Core Product Advantage: Amesite's flagship product, NurseMagic™, reduces documentation time for nurses and caregivers from 20 minutes to just 20 seconds, enhancing operational efficiency and is utilized by over 100 professions across 50 states and 21 countries, showcasing its market potential.
- Market Positioning and Compliance: Built on proprietary AI trained on industry-specific data, NurseMagic™ meets HIPAA regulations while improving accuracy and efficiency, indicating the company's strong competitive edge and compliance capabilities in the healthcare sector.
See More
Amesite Partners with Homecare Tech Platform for NurseMagic Integration
- Strategic Partnership Agreement: Amesite Inc. has signed an Electronic Transactions Trading Partner Agreement with a leading homecare technology platform, establishing itself as a compliant trading partner, which is expected to enhance the application of its AI platform NurseMagic™ in the non-acute care market, valued at approximately $1.55 trillion.
- Integration Advantages: By connecting with this platform, NurseMagic™ can streamline electronic visit verification (EVV) processes using standardized formats mandated by CMS and the 21st Century Cures Act, thereby improving compliance efficiency and operational convenience for clients.
- Revenue Growth Momentum: Amesite achieved a 69% quarter-over-quarter revenue increase in Q2 2026, with a 63% revenue growth following the launch of its census-based enterprise subscription model, indicating strong growth potential in the non-acute care market.
- Industry Recognition: NurseMagic™ was named a finalist for Nurse.org's
See More
Amesite's NurseMagic™ Nominated for Best AI Nursing Tool
- Industry Recognition: Amesite's AI healthcare platform, NurseMagic™, has been nominated as a finalist in the AI Nursing Tool category of Nurse.org's 'Best of Nursing Awards', highlighting its impact and credibility in the healthcare sector, thereby enhancing the company's competitive position in the estimated $460–510 billion U.S. post-acute care market.
- Significant Revenue Growth: Following the launch of NurseMagic™ Teams+ in May 2025, the company reported a 2.4x quarter-over-quarter revenue increase, with an 82% revenue growth in the subsequent quarter after launching the enterprise tier, and a further 69% increase in the following period, indicating strong market demand and profitability.
- User-Driven Expansion: By prioritizing service to nurses and caregivers, NurseMagic™ rapidly scaled across all 50 states and over 20 countries, establishing an engaged user community that not only validated the product's effectiveness in clinical workflows but also laid the groundwork for enterprise sales.
- Technological Innovation and Market Potential: The AI-native EMR system of NurseMagic™ is designed to coexist with or replace legacy systems, expected to drive double-digit annual growth in the long-term care and post-acute software market, further solidifying Amesite's market share in this rapidly growing sector.
See More
Clearwater Analytics (CWAN) Acquired by Private Equity Consortium for $8.4 Billion
- Acquisition Announcement: A consortium of private equity firms led by Permira and Warburg Pincus has announced a deal to acquire Clearwater Analytics for approximately $8.4 billion, including debt, indicating strong market interest in investment and accounting software companies.
- Stock Price Reaction: Clearwater Analytics shares surged 7.6% to $23.93 in pre-market trading, reflecting positive investor sentiment regarding the acquisition news, which may enhance the company's future market performance.
- Market Impact: This acquisition not only provides Clearwater Analytics with financial backing but also has the potential to accelerate its technological innovation and market expansion, strengthening its position in the highly competitive software industry.
- Industry Trend: With private equity firms continuing to invest in the software sector, more similar transactions are expected, further consolidating market resources and enhancing industry competitiveness.
See More
